搜尋結果
The Novavax COVID-19 vaccine, sold under the brand names Nuvaxovid and Covovax, [1] among others, is a subunit COVID-19 vaccine developed by Novavax and the Coalition for Epidemic Preparedness Innovations (CEPI). [29] Medical uses. The Novavax COVID‑19 vaccine is indicated for active immunization to prevent COVID‑19 caused by SARS-CoV-2. [4]
- AU: B1
- Intramuscular
- Covovax, Nuvaxovid
- SARS-CoV-2
Novavax, Inc. is an American biotechnology company based in Gaithersburg, Maryland, that develops vaccines to counter serious infectious diseases. Prior to 2020, company scientists developed experimental vaccines for influenza and respiratory syncytial virus (RSV), as well as Ebola and other emerging infectious diseases.
- 1987; 36 years ago
- Gaithersburg, Maryland, U.S.
- 1,541 (2022)
- US$1.982 billion (2022)
Novavax Subunit/virus-like particle United States December 2021 A "recombinant nanoparticle vaccine" Covaxin Inactivated India January 2021 Valneva Inactivated France, Austria April 2022 Sanofi–GSK Subunit France, United Kingdom November 2022 Based on
The Novavax COVID-19 vaccine, sold under the brand names Nuvaxovid and Covovax, is a subunit COVID-19 vaccine candidate developed by Novavax and the Coalition for Epidemic Preparedness Innovations. Full (4) Australia Canada Japan South Korea
e. The Oxford–AstraZeneca COVID‑19 vaccine, sold under the brand names Covishield [31] and Vaxzevria [1] [32] among others, is a viral vector vaccine for the prevention of COVID-19. It was developed in the United Kingdom by Oxford University and British-Swedish company AstraZeneca, [33] [34] [35] using as a vector the modified chimpanzee ...
- AU: B1
- SARS-CoV-2
- Vaxzevria, Covishield
- Viral vector
CoronaVac, also known as the Sinovac COVID-19 vaccine, is a whole inactivated virus COVID-19 vaccine developed by the Chinese company Sinovac Biotech. It was phase III clinically trialled in Brazil, Chile, Indonesia, the Philippines, and Turkey and relies on traditional technology similar to other inactivated-virus COVID-19 vaccines, such as the Sinopharm BIBP vaccine, another Chinese vaccine ...
Novavax January 31, 2022 July 19, 2022 (ages 18+) August 1, 2022 No No Covaxin March 26, 2021 (ages 18+) November 5, 2021 (ages 2–18) Pending No No No Astrazeneca — — No No No Sanofi–GSK No No No No No
